Azitromycin for chronic eosihophilic rhinosinusitis with nasal polyp: a placebo-controlled trial

Página do item simplificado
dc.creatorIsamara Simas de Oliveira
dc.creatorAlessandro Fernandes Guimarães
dc.creatorGabriela Rafael Arantes Pêgas
dc.creatorCarla Jorge Machado
dc.creatorGiovanni Dantas Cassali
dc.creatorPaulo Crossara
dc.creatorFlávio Barbosa Nunes
dc.creatorHelena Maria Gonçalves Becker
dc.creatorRoberto Eustáquio Santos Guimarães
dc.date.accessioned2023-07-10T19:54:31Z
dc.date.accessioned2025-09-09T00:58:39Z
dc.date.available2023-07-10T19:54:31Z
dc.date.issued2020-07-10
dc.format.mimetypepdf
dc.identifier.doi10.4193/Rhin20.071
dc.identifier.issn03000729
dc.identifier.urihttps://hdl.handle.net/1843/56040
dc.languagepor
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofRhinology
dc.rightsAcesso Aberto
dc.subjectAspirina
dc.subjectAzitromicina
dc.subjectEndoscopia
dc.subjectEosinófilos
dc.subjectPólipos Nasais
dc.subject.otherAspirin
dc.subject.otherAzithromycin
dc.subject.otherEndoscopy
dc.subject.otherEosinophils
dc.subject.otherNasal polyposis
dc.titleAzitromycin for chronic eosihophilic rhinosinusitis with nasal polyp: a placebo-controlled trial
dc.typeArtigo de periódico
local.citation.epage617
local.citation.issue6
local.citation.spage610
local.citation.volume58
local.description.resumoBackground: Chronic eosinophilic rhinosinusitis with nasal polyps (CRSwNP eosinophilic) is characterised by the formation of benign and bilateral nasal polyps. We aimed to compare the effectiveness of azithromycin as an immunomodulator with the use of a placebo in patients presenting with CRSwNP concomitant with asthma and aspirin intolerance after 3 months of treatment and at a 1-year follow-up.Methodology: We performed a randomised, double-blind, placebo-controlled trial. Patients received 500 mg azithromycin orally three times/week for 12 weeks. Improvement was evaluated by staging, the Sino-Nasal Outcome Test (SNOT-22), and nasal polyp biopsy. Data collected at pretreatment and 3 months posttreatment were compared. Quality of life was evaluated at the 1-year follow-up. Results: Twenty-seven and 21 patients were treated with azithromycin and a placebo, respectively. The medication was well tolerated overall. Twenty patients (74%) in the azithromycin group and three patients (14%) in the placebo group were not referred for surgery at the end of the 3-month treatment. Regarding subjective improvement, there was a median decrease only in the azithromycin group, and the between-group difference was significant. SNOT-22 improvement was maintained in the azithromycin group at the 1-year follow-up. Conclusions: Azithromycin could be considered a therapeutic option for patients presenting with CRSwNP concomitant with asthma and aspirin intolerance.
local.publisher.countryBrasil
local.publisher.departmentICB - DEPARTAMENTO DE PATOLOGIA
local.publisher.departmentMED - DEPARTAMENTO DE MEDICINA PREVENTIVA SOCIAL
local.publisher.departmentMED - DEPARTAMENTO DE OFTALMOLOGIA E OTORRINOLARINGOLOGIA
local.publisher.initialsUFMG
local.url.externahttps://www.rhinologyjournal.com/Abstract.php?id=2662

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Azithromycin for chronic eosinophilic rhinosinusitis with pdfa.pdf
Tamanho:
173.34 KB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG